
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Fascin 2 CRISPR Activation Plasmid (m) | sc-433603-ACT | 20 µg | $397.00 | |||
Fascin 2 CRISPR Activation Plasmid (m2) | sc-433603-ACT-2 | 20 µg | $397.00 |
Mouse Fscn2 encodes Fascin 2, an actin-bundling protein that organizes parallel F-actin arrays and supports membrane protrusions, cell shape, and cytoskeletal stability. Fascin-family proteins contribute to actin filament remodeling that interfaces with adhesion dynamics and motility-associated processes, linking cytoskeletal architecture to mechanotransduction and polarized cellular organization. In sensory and epithelial contexts, Fascin 2 is associated with specialized actin-rich structures, making it relevant for studying cytoskeletal maintenance and tissue integrity. Dysregulated actin bundling and fascin-mediated remodeling have been implicated in cellular dysfunction across degenerative and proliferative disease models, supporting investigation of Fscn2-dependent pathways in mouse systems.
Fascin 2 CRISPR Activation Plasmid (m) provides a targeted, non-destructive approach to upregulating endogenous Fscn2 expression without altering the underlying DNA sequence.
Fascin 2 CRISPR Activation Plasmid (m) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the Fscn2 locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the Fscn2 transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous Fascin 2 expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native Fscn2 locus and enabling the study of Fascin 2-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of Fascin 2 pathway restoration in tumor cells with silenced or reduced Fscn2 expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.